INFUSIONAL CYCLOPHOSPHAMIDE, DOXORUBICIN, AND ETOPOSIDE IN RELAPSED AND RESISTANT NON-HODGKINS-LYMPHOMA - EVIDENCE FOR A SCHEDULE-DEPENDENT EFFECT FAVORING INFUSIONAL ADMINISTRATION OF CHEMOTHERAPY

被引:61
作者
SPARANO, JA [1 ]
WIERNIK, PH [1 ]
LEAF, A [1 ]
DUTCHER, JP [1 ]
机构
[1] YESHIVA UNIV ALBERT EINSTEIN COLL MED, JACK WEILER HOSP, BRONX, NY 10461 USA
关键词
D O I
10.1200/JCO.1993.11.6.1071
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: This study attempted to determine the efficacy of cyclophosphamide (C), doxorubicin (D), and etoposide (E) administered as a continuous intravenous (IV) infusion (infusional CDE) over 4 days in patients with relapsed or resistant non-Hodgkin's lymphoma (rNHL) and in patients with previously untreated (uNHL) who had poor prognostic features. Patients and Methods: Fifty-eight patients with rNHL and 10 patients with uNHL received infusional CDE every 28 or more days; all but one had intermediate- to high- grade histology. The cumulative doses of C, D, and E administered per treatment cycle were 750 mg/m2, 50 mg/m2, and 240 mg/m2, respectively. In the rNHL group, all patients had previously received C, most (81%) had received D, and a minority (16%) had received E. Results: Objective response occurred in 30 patients with rNHL (52%; 95% confidence interval, 39% to 65%); 10 patients had a complete response (CR) (17%; 95% confidence interval, 7% to 27%). Eleven patients (19%) remain progression-free (median follow-up, 22 months; range, 10+ to 38+), and six patients (10%) are disease-free (median follow-up, 25 months; range, 10+ to 38+). Among 10 patients with uNHL, eight (80%) had a CR, and none have relapsed (median follow-up, 11 months; range, 9+ to 24+). Toxicity was primarily hematologic. Two treatment-related deaths (3%) occurred, both attributable to infection in the relapsed or resistant group. Conclusion: Infusional CDE produced a CR in substantial proportion of patients who had previously been exposed to at least two of the agents administered as an IV bolus, suggesting a schedule-dependent effect in favor of the infusional administration of certain cytotoxic agents in patients with lymphoid neoplasms. In addition, infusional CDE was effective and tolerable in patients with poor-prognosis NHL when used as initial therapy, and merits further study in that setting.
引用
收藏
页码:1071 / 1079
页数:9
相关论文
共 30 条
[1]  
[Anonymous], 1982, CANCER, V49, P2112
[2]   EFFECTIVE TREATMENT OF ADVANCED MULTIPLE-MYELOMA REFRACTORY TO ALKYLATING-AGENTS [J].
BARLOGIE, B ;
SMITH, L ;
ALEXANIAN, R .
NEW ENGLAND JOURNAL OF MEDICINE, 1984, 310 (21) :1353-1356
[3]  
BELLAMY WT, 1988, CANCER RES, V48, P6303
[4]   CANCER STATISTICS, 1991 [J].
BORING, CC ;
SQUIRES, TS ;
TONG, T .
CA-A CANCER JOURNAL FOR CLINICIANS, 1991, 41 (01) :19-36
[5]   RESULTS OF MIME SALVAGE REGIMEN FOR RECURRENT OR REFRACTORY LYMPHOMA [J].
CABANILLAS, F ;
HAGEMEISTER, FB ;
MCLAUGHLIN, P ;
VELASQUEZ, WS ;
RIGGS, S ;
FULLER, L ;
SMITH, T .
JOURNAL OF CLINICAL ONCOLOGY, 1987, 5 (03) :407-412
[6]  
CHAO NJ, 1990, BLOOD, V76, P1293
[7]   PROGNOSTIC FACTORS IN AGGRESSIVE MALIGNANT-LYMPHOMAS - DESCRIPTION AND VALIDATION OF A PROGNOSTIC INDEX THAT COULD IDENTIFY PATIENTS REQUIRING A MORE INTENSIVE THERAPY [J].
COIFFIER, B ;
GISSELBRECHT, C ;
VOSE, JM ;
TILLY, H ;
HERBRECHT, R ;
BOSLY, A ;
ARMITAGE, JO .
JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (02) :211-219
[8]  
FISHER RI, 1992, P AN M AM SOC CLIN, V11, P15
[9]   NON-HODGKIN LYMPHOMA IN JAMAICA AND ITS RELATION TO ADULT T-CELL LEUKEMIA-LYMPHOMA [J].
GIBBS, WN ;
LOFTERS, WS ;
CAMPBELL, M ;
HANCHARD, B ;
LAGRENADE, L ;
CRANSTON, B ;
HENDRIKS, J ;
JAFFE, ES ;
SAXINGER, C ;
ROBERTGUROFF, M ;
GALLO, RC ;
CLARK, J ;
BLATTNER, WA .
ANNALS OF INTERNAL MEDICINE, 1987, 106 (03) :361-368
[10]  
HANSEN MM, 1980, CANCER TREAT REP, V64, P1135